PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,361 stories, page 733 of 773

Advanced search
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Announcement of new structure｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Launch of Nanozora® 30mg Autoinjector for S.C. Injection｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for NanozoraⓇ

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Launch of Nanozora® 30 mg Syringes for Subcutaneous Injection｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Notification of Application for Approval to Manufacture and Market Rheumatoid Arthritis Therapy Nanozora® 30mg Autoinjectors for S.C. Injection in Japan｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Cetylpyridinium chloride hydrate (CPC) confirmed to have an action of inactivating SARS-CoV-2 variants

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Former All Blacks players Richard McCaw and Daniel Carter appointed Lipovitan Ambassadors｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Data from Japan's First Phase II/III Clinical Trial of NANOBODY® Ozoralizumab for Rheumatoid Arthritis Presented at the 36th Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Cetylpyridinium chloride hydrate (CPC) confirmed to have an action inactivating SARS-CoV-2

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Taisho Pharmaceutical appointed as Premium Global Partner of New Zealand Rugby｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Taisho Pharmaceutical appointed as Official Supplier of Rugby World Cup France 2023｜Taisho Pharmaceutical Holdings

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Group Companies Worldwide｜Taisho Pharmaceutical

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

Group Companies in Japan｜Taisho Pharmaceutical

Taisho PharmaceuticalOriginal source
🇯🇵Industrytaisho.co.jpTier 1 · Company source

List of Business Locations｜Taisho Pharmaceutical

Taisho PharmaceuticalOriginal source
🇯🇵Devicessysmex.co.jpTier 1 · Company source

ç ”ç©¶é–‹ç™ºãƒ‹ãƒ¥ãƒ¼ã‚¹ | シスメックス - Sysmex

Sysmex (IR News)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Medicamenti per uso umano omologati contenenti nuovi principi attivi

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Médicaments à usage humain autorisés contenant de nouveaux principes actifs

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Swissmedic eGov

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Updated specification documents

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Medical devices

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Complementary & herbal medicines

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

PDF invoice by e-mail

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Batch recalls human medicines

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Medicines > Out-of-Stock

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Authorisations of human medicinal products with a new active substance and additional indications 2025

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

VoraxazeTM, Pulver zur Herstellung einer Injektionslösung (Glucarpidase)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Rhapsido®, Filmtabletten (Remibrutinibum)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Rezzayo®, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung (Rezafunginum)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

mNEXSPIKETM, Dispersion zur i.m. Injektion (SARS-CoV-2 XBB.1.5 mRNA)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Galli Ad, Radionuklidgenerator (68Ge)Germaniumchlorid / (68Ga)Galliumchlorid)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Celldemic®, Injektionssuspension in Fertigspritzen (Haemagglutininum influenzae A (H5N1))

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Ambelvist®, Injektionslösung (Gadoquatranum)

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Quality/CMC Assessor/in (80–100%) – Schwerpunkt Impfstoffe & Blutprodukte

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Über uns

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Neue Informationen zur Einführung von eCTD v4.0

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

eGov-Portal (Fachanwendungen)

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Revision der Wegleitung Zulassung Biosimilar

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Notwendige Anpassungen für die Ausstellung von Betriebsbewilligungen und GMP-Zertifikaten für Wirkstoffhersteller

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Neuer strategischer Ansatz zur Minimierung von Tierversuchen bei der Entwicklung von Arzneimitteln

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

GMP-Konformität ausländischer Hersteller

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Anpassung der Wegleitung Einfuhr eines Humanarzneimittels nach Art. 14 Abs. 2 und 3 HMG (Parallelimport)

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Die neue Pharmacopoea Helvetica 13

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Komplementär- und Phytoarzneimittel

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

PDF Rechnung per E-Mail

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Chargenrückrufe Humanarzneimittel

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Malignes neuroleptisches Syndrom im Zusammenhang mit antipsychotischer Behandlung

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Out-of-Stock – Syntocinon Nasenspray, Lösung; Oxytocin 40 I.E./ml

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Out-of-Stock – Cablivi 10 mg, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Arzneimittel > Out-of-Stock (Lieferengpässe)

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Auswertung der Haemovigilance Meldungen 2025

Swissmedic - Medical Devices & SaMDOriginal source
🇨🇭Regulatoryswissmedic.chTier 1 · Regulatory source

Zugelassene Humanarzneimittel mit neuen Wirkstoffen

Swiss Agency for Therapeutic Products (Swissmedic)Original source
🌍Industrysotio.comTier 1 · Company source

FDA Grants Fast Track Designation to SOTIO’s SOT109, a CD...

SOTIO Biotech (PPF Group)Original source
🌍Industrysotio.comTier 1 · Company source

FDA Grants Fast Track Designation to SOTIO’s SOT106 ADC f...

SOTIO Biotech (PPF Group)Original source
🌍Industrysotio.comTier 1 · Company source

European Patent Office Confirms Patent Protection for SOT...

SOTIO Biotech (PPF Group)Original source
🇺🇸Industrysolidbio.comTier 1 · Company source

Our Commitment - Solid Biosciences

Solid BiosciencesOriginal source
🇫🇷Investorsofinnovapartners.comTier 2 · Direct publisher

Verley secures $38 million Series A to commercialize high-performance whey protein ingredients through precision fermentation — Sofinnova Partners

Sofinnova PartnersOriginal source
🇫🇷Investorsofinnovapartners.comTier 2 · Direct publisher

Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth — Sofinnova Partners

Sofinnova PartnersOriginal source
🇫🇷Investorsofinnovapartners.comTier 2 · Direct publisher

News 23 March, 2026 Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development

Sofinnova PartnersOriginal source